Celldex Therapeutics (CLDX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.94
- Estimate
- -$1.05
- Surprise
- +10.2%
- Revenue (period 2026-06-30)
- $22,000
- Score today
- 5.1/10
Revenue source: mixed.
How the report landed
Celldex Therapeutics (CLDX) reported a narrower loss than forecast — adjusted EPS of -$0.94 against the -$1.05 estimate (a 10.2% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates CLDX Sell at 5.1/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's +10.2% surprise compares with a -7.1% four-quarter average. Next scheduled report: 2026-11-09.
What argues against it
- Quality below floor (1.5 < 4.0)
- Momentum score 1.3/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $28.07
- Price target
- $54.87
- Stop
- $27.07
- Upside to target
- +95.5%
- Reward-to-risk
- 10.2:1
Model outputs from TrendMatrix’s engine as of 2026-10-14 — shown for context, not personalized investment advice.
CLDX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.22B
- P/E (fwd)
- -6.7
- 52-week range
- $22.10–$45.14
- Off 52-week high
- 37.8%
- RSI (14)
- 31
- Volume vs avg
- 0.13×
- Score today
- 5.1/10